Difference between revisions of "Histrelin (Vantas)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
m |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
Class/mechanism: LH-RH agonist. Histrelin acetate inhibits gonadotropin secretion by desensitizing responsiveness of the pituitary gonadotropin which, in turn, causes a reduction in testicular steroidogenesis.<ref name="insert">[http://www.endo.com/File%20Library/Products/Prescribing%20Information/VANTAS.pdf Histrelin (Vantas) package insert]</ref><ref>[[Media:Histrelin.pdf | Histrelin (Vantas) package insert (locally hosted backup)]]</ref><ref>[http://www.vantasimplant.com/ Vantas implant manufacturer's website]</ref> | Class/mechanism: LH-RH agonist. Histrelin acetate inhibits gonadotropin secretion by desensitizing responsiveness of the pituitary gonadotropin which, in turn, causes a reduction in testicular steroidogenesis.<ref name="insert">[http://www.endo.com/File%20Library/Products/Prescribing%20Information/VANTAS.pdf Histrelin (Vantas) package insert]</ref><ref>[[Media:Histrelin.pdf | Histrelin (Vantas) package insert (locally hosted backup)]]</ref><ref>[http://www.vantasimplant.com/ Vantas implant manufacturer's website]</ref> | ||
| − | <br>Route: | + | <br>Route: SC |
<br>Extravasation: no information | <br>Extravasation: no information | ||
| Line 14: | Line 14: | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://www.endo.com/File%20Library/Products/Prescribing%20Information/VANTAS.pdf Histrelin (Vantas) package insert]<ref name="insert"></ref> | *[http://www.endo.com/File%20Library/Products/Prescribing%20Information/VANTAS.pdf Histrelin (Vantas) package insert]<ref name="insert"></ref> | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Brand name:''' Vantas | ||
==References== | ==References== | ||
| Line 19: | Line 22: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| − | + | [[Category:Subcutaneous medications]] | |
[[Category:Endocrine therapy]] | [[Category:Endocrine therapy]] | ||
[[Category:LH-RH agonist]] | [[Category:LH-RH agonist]] | ||
Revision as of 19:34, 23 July 2018
General information
Class/mechanism: LH-RH agonist. Histrelin acetate inhibits gonadotropin secretion by desensitizing responsiveness of the pituitary gonadotropin which, in turn, causes a reduction in testicular steroidogenesis.[1][2][3]
Route: SC
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
History of changes in FDA indication
- 10/12/2004: Initial FDA approval "in the palliative treatment of advanced prostate cancer."
Patient drug information
Also known as
- Brand name: Vantas